Want to see TMO full AI Analyst Report?
Revenue by Segment
Breaks down revenue across various business segments, revealing which areas are contributing most to growth and where there may be potential for expansion or risk.Thermo Fisher’s top-line lift is concentrated in Laboratory Products and Life Sciences Solutions — both recovering from the 2022 trough and driving the company’s raised 2026 guide (with Clario adding meaningful reported revenue and accretion). That strength masks weak organic demand in Analytical Instruments and pockets of Specialty Diagnostics softness (academic/government and China), so near-term upside relies more on M&A, product launches and margin productivity than broad-based end‑market recovery; rising eliminations also suggest acquisition-related intracompany flows inflating reported revenue.
Date | Eliminations | Life Sciences Solutions | Analytical Instruments | Speciality Diagnostics | Laboratory Products |
|---|---|---|---|---|---|
Jun 30, 2026 | -$565.00M | $2.81B | $1.85B | $1.21B | $6.69B |
Mar 31, 2026 | -$524.00M | $2.64B | $1.72B | $1.14B | $6.04B |
Dec 31, 2025 | -$546.00M | $2.95B | $2.21B | $1.22B | $6.38B |
Sep 30, 2025 | -$503.00M | $2.59B | $1.89B | $1.17B | $5.97B |
Jun 30, 2025 | -$501.00M | $2.50B | $1.73B | $1.13B | $6.00B |
Mar 31, 2025 | -$482.00M | $2.34B | $1.72B | $1.15B | $5.64B |
Dec 31, 2024 | -$487.00M | $2.60B | $2.19B | $1.16B | $5.94B |
Sep 30, 2024 | -$467.00M | $2.39B | $1.81B | $1.13B | $5.74B |
Jun 30, 2024 | -$470.00M | $2.35B | $1.78B | $1.12B | $5.76B |
Mar 31, 2024 | -$460.00M | $2.29B | $1.69B | $1.11B | $5.72B |